Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Biological Chemistry

• Publication date

  1993-07-05

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 8390996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.

  1993cited by this paper
• Therapeutic Applications of Oligonucleotides

  1992cited by this paper
• Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides.

  1992cited by this paper
• Specificity of antisense oligonucleotides in vivo.

  1992cited by this paper
• Implication of RNA structure on antisense oligonucleotide hybridization kinetics.

  1992cited by this paper
• Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures.

  1992cited by this paper
• Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides.

  1992cited by this paper
• Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

  1992cited by this paper
• Antisense inhibition of oncogene expression.

  1992cited by this paper
• The use of oligonucleotide probes containing 2'-deoxy-2'-fluoronucleosides for regiospecific cleavage of RNA by RNase H from Escherichia coli.

  1992cited by this paper
• Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

  1991cited by this paper
• Prothymosin alpha antisense oligomers inhibit myeloma cell division.

  1991cited by this paper
• Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor beta 3.

  1991cited by this paper
• Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages.

  1991cited by this paper
• Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes).

  1991cited by this paper
• Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages.

  1991cited by this paper
• Antisense agents in pharmacology.

  1990cited by this paper
• Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.

  1990cited by this paper
• Secondary structure in formylmethionine tRNA influences the site-directed cleavage of ribonuclease H using chimeric 2'-O-methyl oligodeoxyribonucleotides.

  1990cited by this paper
• Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis.

  1990cited by this paper
• Effects of oligo sequence and chemistry on the efficiency of oligodeoxyribonucleotide-mediated mRNA cleavage.

  1990cited by this paper
• Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells.

  1990cited by this paper
• Transcriptional activation of a conserved sequence element by ras requires a nuclear factor distinct from c-fos or c-jun.

  1990cited by this paper
• RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds.

  1989cited by this paper
• Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides.

  1989cited by this paper
• Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates.

  1989cited by this paper
• Antimessenger oligodeoxyribonucleotides: an alternative to antisense RNA for artificial regulation of gene expression--a review.

  1988cited by this paper
• Oligodeoxynucleotides as inhibitors of gene expression: a review.

  1988cited by this paper
• Theoretical considerations on the "spine of hydration" in the minor groove of d(CGCGAATTCGCG).d(GCGCTTAAGCGC): Monte Carlo computer simulation.

  1988cited by this paper
• Comparative hybrid arrest by tandem antisense oligodeoxyribonucleotides or oligodeoxyribonucleoside methylphosphonates in a cell-free system.

  1988cited by this paper
• Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity.

  1987cited by this paper
• Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides.

  1987cited by this paper
• Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H.

  1987cited by this paper
• Oligodeoxynucleotide stability in subcellular extracts and culture media.

  1986cited by this paper
• Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length.

  1986cited by this paper
• Destabilization of messenger RNA/complementary DNA duplexes by the elongating 80 S ribosome.

  1986cited by this paper
• The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations.

  1986cited by this paper
• Inhibition of rabbit globin mRNA translation by sequence-specific oligodeoxyribonucleotides.

  1985cited by this paper
• Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

  1983cited by this paper
• Base-stacking and base-pairing contributions to helix stability: thermodynamics of double-helix formation with CCGG, CCGGp, CCGGAp, ACCGGp, CCGGUp, and ACCGGUp.

  1983cited by this paper
• A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene

  1982cited by this paper
• Structure of a B-DNA dodecamer. III. Geometry of hydration.

  1981cited by this paper
• Biochemical and biological effects of nonionic nucleic acid methylphosphonates.

  1981cited by this paper

• Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeutics

  2026cites this paper
• Omega Nucleic Acids (ΩNA), Ultimate Nucleic Acids for Future Technology

  2026cites this paper
• Manufacturing and testing of a polymer formulation for long-time release delivery of antisense oligonucleotides in hiPSC-derived motoneurons

  2026cites this paper
• RNA-Based Therapies for Treating Monogenic Cardiomyopathies.

  2026cites this paper
• RNA-Targeting Techniques: A Comparative Analysis of Modern Approaches for RNA Manipulation in Cancer Research and Therapeutics

  2025cites this paper
• Artificial intelligence in the development of small nucleic acid therapeutics: toward smarter and safer medicines.

  2025cites this paper
• Transforming cancer immunotherapy: Overcoming immunosuppression in tumors via gene silencing techniques based on nanoparticles

  2025cites this paper
• Optimisation of Heated Electrospray Ionisation Parameters to Minimise In‐Source Generated Impurities in the Analysis of Oligonucleotide Therapeutics

  2025cites this paper
• Contract to kill: GNAS mutation

  2025cites this paper
• Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems.

  2025cites this paper
• Long Non-coding RNA Based Therapy for Cardiovascular Disease

  2025cites this paper
• ASOptimizer: optimizing chemical diversity of antisense oligonucleotides through deep learning

  2025cites this paper
• Chemical Modifications in Nucleic Acid Therapeutics.

  2025cites this paper
• Dravet syndrome: novel insights into SCN1A-mediated epileptic neurodevelopmental disorders within the molecular diagnostic-therapeutic framework

  2025cites this paper
• Synthesis of 4′‐C‐α‐Aminoethoxy‐2′‐O‐Methyl‐5‐Methyl‐ and 5‐Propynyl‐Uridine Phosphoramidites for Structurally Optimized Antisense Oligonucleotides

  2025cites this paper
• Targeting and engineering biomarkers for prostate cancer therapy.

  2025cites this paper
• Harnessing BET-Bromodomain Assisted Nuclear Import for Targeted Subcellular Localization and Enhanced Efficacy of Antisense Oligonucleotides

  2025cites this paper
• Targeting FANCM by antisense oligonucleotides in ALT-positive cancers

  2025cites this paper
• Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

  2025cites this paper
• Toxicity of Antisense Oligonucleotides is Determined by the Synergistic Interplay of Chemical Modifications and Nucleotide Sequences, Not by Either Factor Alone

  2025cites this paper
• Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders

  2025cites this paper
• A symphony of signals: the intricate role of lncRNAs in dermatological disorders

  2025cites this paper
• Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment

  2025cites this paper
• Targeting Regulatory Noncoding RNAs in Human Cancer: The State of the Art in Clinical Trials

  2025cites this paper
• Antisense Oligonucleotides: A Promising Advancement in Neurodegenerative Disease Treatment.

  2025cites this paper
• Genetic therapies for neurological diseases

  2025cites this paper
• Nanomaterials‐Based Targeting of Long Non‐Coding RNAs in Cancer: A Cutting‐Edge Review of Current Trends

  2024cites this paper
• Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders

  2024cites this paper
• Advances on the Mechanisms and Therapeutic Strategies in Non-coding CGG Repeat Expansion Diseases

  2024cites this paper
• Targeting and engineering long non-coding RNAs for cancer therapy

  2024cites this paper
• Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma

  2024cites this paper
• Advances and prospects of RNA delivery nanoplatforms for cancer therapy

  2024cites this paper
• Nucleic acid therapeutics: Past, present, and future

  2024cites this paper
• Therapeutic targeting of RNA for neurological and neuromuscular disease

  2024cites this paper
• Treatability of the KMT2-Associated Neurodevelopmental Disorders Using Antisense Oligonucleotide-Based Treatments

  2024cites this paper
• Survivin (BIRC5): Implications in cancer therapy.

  2024cites this paper
• Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing

  2024cites this paper
• Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.

  2024cites this paper
• Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.

  2024cites this paper
• Oligonucleotide therapies for nonalcoholic steatohepatitis

  2024cites this paper
• Comparative molecular dynamics calculations of duplexation of chemically modified analogs of DNA used for antisense applications

  2024cites this paper
• Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape

  2024cites this paper
• Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1

  2023cites this paper
• Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases

  2023cites this paper
• Future directions for medicinal chemistry in the field of oligonucleotide therapeutics

  2023cites this paper
• The Current Status of Antisense Gene Therapies for Bacteria-caused Diseases-Challenges and Opportunities.

  2023cites this paper
• Aberrant splicing in human cancer: An RNA structural code point of view

  2023cites this paper
• Long Non-Coding RNAs, Cell Cycle, and Human Breast Cancer

  2023cites this paper
• Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges.

  2023cites this paper
• Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1

  2023cites this paper
• Antisense oligonucleotide based therapeutics and its applications against bacterial infections

  2023cites this paper
• An RNA-based system to study hepatitis B virus replication and evaluate antivirals

  2023cites this paper
• Development of Nucleic Acid Medicines Based on Chemical Technology.

  2023cites this paper
• Oligonucleotides Containing C5‐Propynyl Modified Arabinonucleic Acids: Synthesis, Biophysical and Antisense Properties

  2023cites this paper
• Drug Discovery Perspectives of Antisense Oligonucleotides

  2023cites this paper
• Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies

  2023cites this paper
• miRNA-Based Technologies in Cancer Therapy

  2023cites this paper
• Splice-Switching Antisense Oligonucleotides Targeting Extra- and Intracellular Domains of Epidermal Growth Factor Receptor in Cancer Cells

  2023cites this paper
• Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic

  2022cites this paper
• Retraction: Ki20227 aggravates apoptosis, inflammatory response, and oxidative stress after focal cerebral ischemia injury

  2022cites this paper
• Brain delivering RNA-based therapeutic strategies by targeting mTOR pathway for axon regeneration after central nervous system injury

  2022cites this paper
• Therapeutic RNA-silencing oligonucleotides in metabolic diseases

  2022cites this paper
• Potential of RH5 Antisense on Plasmodium falciparum Proliferation Abatement

  2022cites this paper
• Lipid nanoparticles for antisense oligonucleotide gene interference into brain border-associated macrophages

  2022cites this paper
• Molecular and Genetic Therapies

  2022cites this paper
• Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis

  2022cites this paper
• Introduction and History of the Chemistry of Nucleic Acids Therapeutics

  2022cites this paper
• A perspective on oligonucleotide therapy: Approaches to patient customization

  2022cites this paper
• Harnessing nucleic acid technologies for human health on earth and in space.

  2022cites this paper
• Promotion of cytoplasmic localization of oligonucleotides by connecting cross-linked duplexes

  2022cites this paper
• Small non-coding RNA therapeutics for cardiovascular disease

  2022cites this paper
• Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects

  2022cites this paper
• Human Protein Tyrosine Phosphatase 1B (PTP1B): From Structure to Clinical Inhibitor Perspectives

  2022cites this paper
• Lipid-based nucleic acid therapeutics with in vivo efficacy.

  2022cites this paper
• Arabinonucleic Acids Containing C5-Propynyl Modifications Form Stable Hybrid Duplexes with RNA that are Efficiently Degraded by E. coli RNase H.

  2022cites this paper
• Evaluation of Gene Expression Knock‐Down by Chemically and Structurally Modified Gapmer Antisense Oligonucleotides

  2022cites this paper
• Modulating T-cell activation with antisense oligonucleotides targeting lymphocyte cytosolic protein 2.

  2022cites this paper
• Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias

  2021cites this paper
• Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease

  2021cites this paper
• Opportunities and challenges for microRNA-targeting therapeutics for epilepsy.

  2021cites this paper
• History of Research on Antisense Oligonucleotide Analogs

  2021cites this paper
• Delivery of oligonucleotide‐based therapeutics: challenges and opportunities

  2021cites this paper
• The current landscape of nucleic acid therapeutics

  2021cites this paper
• Divalent Metal Ions Boost Effect of Nucleic Acids Delivered by Cell-Penetrating Peptides

  2021cites this paper
• Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders

  2021cites this paper
• Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model

  2021cites this paper
• Antisense Oligonucleotide Therapeutics for Neurodegenerative Disorders

  2021cites this paper
• Antisense Oligonucleotides Potent and Selective Knockdown of Tyrosine Kinase 2 by

  2021cites this paper
• Cationic oligonucleotide derivatives and conjugates: A favorable approach for enhanced DNA and RNA targeting oligonucleotides

  2021cites this paper
• Role of noncoding RNA in drug resistance of prostate cancer

  2021cites this paper
• Functional interplay between long non-coding RNAs and the Wnt signaling cascade in osteosarcoma

  2021cites this paper
• Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles

  2021cites this paper
• Antisense technology: an overview and prospectus

  2021cites this paper
• Quantification of Antisense Oligonucleotides by Splint Ligation and Quantitative Polymerase Chain Reaction

  2021cites this paper
• Advances of Antisense Oligonucleotide Technology in the Treatment of Hereditary Neurodegenerative Diseases

  2021cites this paper
• BIOANALYSIS AND BIOTRANSFORMATION OF OLIGONUCLEOTIDE THERAPEUTICS BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY.

  2020cites this paper
• A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics

  2020cites this paper
• Advances in oligonucleotide drug delivery

  2020cites this paper
• Novel EGFP reporter cell and mouse models for sensitive imaging and quantification of exon skipping

  2020cites this paper
• From desktop to benchtop - Developing computational tools for organic and medicinal chemistry

  2020cites this paper